Updated November 6, 2026: The fee proposal discussed below is now described in the past tense, including in the title and the closing assessment. The Oregon Health Authority did not move forward with it: its September 22 statement said the agency would not file final rules or adopt the proposed fee increases. It began a separate rulemaking on proposed changes unrelated to fees, with a planned effective date of January 15, 2027; its rulemaking page shows Rules Advisory Committee meetings on November 2 and 4.
Updated October 15, 2026: This piece now includes findings from a mystery-shopper study of Oregon’s service centers, published August 27 in Health Affairs Scholar and based on calls made in mid-2025. The description of the program’s screening requirements has also been made more precise.
Updated October 12, 2026: On September 22, the Oregon Health Authority said it would not adopt the fee increases described below, citing feedback from its advisory board, its rule committees and public comment. It said it would open a separate rulemaking on changes unrelated to fees, planned to take effect on January 15, 2027. The fee discussion below describes the proposal as it stood in August.
Updated and corrected October 9, 2026. Correction: this piece originally described the study as the first peer-reviewed safety and outcomes study of a state-licensed psilocybin program, and as the first peer-reviewed evidence about what happens to the program’s clients. A peer-reviewed analysis of adverse-event counts from Oregon’s state reporting system was published in Frontiers in Psychiatry in May 2026. The claim has been narrowed throughout: this is the first peer-reviewed study to follow individual clients and report both safety and symptom outcomes. Update: the piece now includes the study’s own figures on participant-reported worsening depression and new thoughts of dying or suicide, and its finding that facilitators recorded one of the four serious adverse reactions. The closing assessment has been revised to reflect them.
Oregon’s psilocybin services program has operated since 2023 with almost no published data on what happens to the people who use it. That changed on August 19, when JAMA Network Open published the first peer-reviewed study to follow individual clients of a state-licensed psilocybin program and report both safety and symptom outcomes. Aggregate adverse-event counts from Oregon’s own reporting system had been published in May; they cannot follow a client after the session. A search of the indexed literature found no earlier peer-reviewed study of individual clients. A smaller preprint that surveyed 88 clients for 30 days, posted in February, has not been peer reviewed. The data arrived in the middle of an Oregon Health Authority rulemaking process considering fee increases that operators said could shut parts of the program down. On September 22 the authority said it would not adopt them.
What the study measured
Led by Todd Korthuis at Oregon Health and Science University, the cohort study tracked 346 clients who completed a single psilocybin session at 24 of Oregon’s 26 licensed service centers, supervised by 83 licensed facilitators. Participants enrolled between November 2024 and March 2026, with follow-up through June. This is not clinical trial data. Participants were not screened, dosed, or monitored under an FDA Investigational New Drug application; they were ordinary clients of a regulated, non-medical service model operating entirely outside the drug-development pathway this desk has spent the year tracking. The study was federally funded, through SAMHSA, NIH, and NIDA, itself a notable detail given the federal government funded research into a program serving a federally Schedule I substance.
What it found
At one month, 92.2 percent of the 321 participants with follow-up data reported benefiting from their session, and 58.6 percent ranked it among the ten most meaningful experiences of their lives. At three months, participants reported real decreases in moderate to severe symptoms of depression, anxiety, and PTSD, alongside broader improvements in wellbeing. Ninety percent of the original cohort was still reporting at that checkpoint. On safety, four participants, 1.2 percent of the cohort, experienced serious adverse behavioral reactions, too few to establish reliable predictors of risk. The researchers flagged inexperience with psychedelics, greater psychological vulnerability, and higher doses as possible contributors.
Only one of those four was recorded by a facilitator as a serious reaction, a client taken to hospital during a session. The other three surfaced in participants’ own follow-up surveys, which reported emergency department visits, new medication, and worsening anxiety or depression that the participants connected to the experience. The surveys also showed a minority getting worse while the averages improved. At three months, 14 of 312 respondents (4.5 percent) reported persistent, worsening depression, up from 9 at one week; six (1.9 percent) reported new thoughts of dying or suicide, up from three; and seven (2.3 percent) said the experience had been harmful. The authors conclude that state reporting rules focused on the day of services may underestimate the true rate of adverse reactions.
Korthuis, who has said he began the project skeptical of dosing people with psilocybin outside a tightly controlled medical setting, described the results as having changed his own view.
“The data has swayed me. These results are very reassuring.”
— Todd Korthuis, MD, MPH, professor of medicine and chief of the Addiction Medicine Section, Oregon Health and Science University
Why this data type matters, independent of the specific numbers
This year’s psychedelic coverage keeps returning to the same distinction: trial-level effect sizes are not the same as what a drug does once it leaves the controlled conditions that produced them. A retrospective study of nineteen patients treated under Switzerland’s medical-exemption framework, examined in this desk’s earlier coverage, found real-world psilocybin outcomes landing closer to ordinary antidepressant performance than to the dramatic figures early trials reported. Oregon’s data tells a different story: benefit rates and symptom reductions that hold up closer to trial-level expectations. That result was generated under a model with no medical clearance or clinician referral, no IND oversight, and facilitators who need no clinical license. Read together, these two real-world datasets, drawn from two entirely different regulatory frameworks, are the closest thing available right now to a natural experiment in what actually determines psilocybin’s real-world performance. The candidates are medical-model oversight itself, or something else entirely: session structure, facilitator training, participant self-selection, factors that may matter more than having a physician in the room.
A fee proposal could have undercut the program that produced this evidence
Marijuana Moment’s reporting on this study’s release surfaced the detail worth sitting with most: Oregon regulators were weighing steep increases to the fees licensed service centers and facilitators pay to operate. Industry participants warned the changes could force closures across the program just as it produced its first client-level evidence on safety and benefit. More than 20,000 people have gone through Oregon’s program since it launched, per reporting on the study’s release, and this cohort of 346 is the first slice of that population tracked in a peer-reviewed study. The authors put it at about 5 percent of the clients served during the study period. Legislators in Colorado, California, and other states weighing their own frameworks have been waiting for exactly this kind of evidence base. Oregon generated it while a fee proposal threatened the service centers producing that evidence; the authority has since said it will not adopt the increases.
A separate study, published August 27 in Health Affairs Scholar, shows what the program looked like from the outside. Researchers led by Danielle Adams and Kevin Xu posed as prospective clients with depression and called Oregon’s licensed service centers between July and September 2025. Of 26 centers in the state’s directory, four had closed before the calls began, and callers reached 15 of the remaining 22. None of the 15 offered take-home or unsupervised psilocybin, none offered to dose without further screening, and none told a caller to stop an antidepressant. The median quoted price for preparation, dosing and integration was $1,900, ranging from $850 to $3,000. No center accepted insurance, though all offered some form of sliding scale. In follow-up interviews in April 2026, staff from five centers described licensing fees as a strain on whether centers could stay open. The calls record what staff told prospective clients at first contact in mid-2025. They do not show what happened in later sessions, or what the seven centers that never answered would have said.
What Korthuis himself flagged as limits
The study’s own lead author was direct about who this model is not for: psilocybin services under this framework are not appropriate for people with psychosis, bipolar disorder, or those who are pregnant. That screening boundary is worth stating plainly, given how much public conversation around state-legal psilocybin access tends to treat it as broadly appropriate for anyone seeking the experience. Korthuis was also careful to frame the result honestly rather than as a blanket endorsement: “There are no magic bullets, and the same is true of psilocybin.”
What this cohort study cannot establish
This is a single cohort study without a control or comparison group, meaning it cannot establish that psilocybin itself, rather than the broader experience of preparation, facilitated dosing, and integration support, produced the reported benefits. Self-selection is a real limitation: people who seek out and pay for a licensed psilocybin session are not a representative cross-section of the population. Ninety percent three-month retention, while strong, still means one in ten participants was not tracked to the final checkpoint. Four serious adverse events in 346 participants is too small a number to support firm conclusions about which specific risk factors predict harm, a limitation the study’s own authors state directly. Without a comparison group, the study also cannot say how much of the worsening depression or new suicidal thinking some participants reported would have occurred without a session.
Why this evidence matters now
This is the first peer-reviewed study to follow individual clients of a state-licensed, non-medical psilocybin program over time. On average the results are more favorable than skeptics of the non-medical service model, this desk included, might have expected going in: symptom scores fell, most participants reported benefit, and serious reactions were uncommon. The same tables show a small minority who worsened and harms that facilitators did not record. Both findings should matter for how Colorado and other states finish designing their own frameworks. The fee increases under consideration when the data arrived are no longer proposed: the Oregon Health Authority said on September 22 that it would not adopt them.